<DOC>
	<DOCNO>NCT00650429</DOCNO>
	<brief_summary>This study conduct examine efficacy tolerability ziprasidone intramuscular ( IM ) , assess effect switch IM oral ziprasidone treatment acute exacerbation schizophrenia schizoaffective disorder Latin American population .</brief_summary>
	<brief_title>A Study Efficacy Safety Ziprasidone Treatment Acute Exacerbation Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder . Inpatients acute exacerbation psychotic symptom . Patients minimum score 40 BPRS scale ( 17 ) . Concurrent treatment antipsychotic agent study drug initiation ( within 12 hour prior study drug initiation ) ; depot agent period two week one cycle , whichever longer , must occur last administration study drug initiation . Treatment antidepressant mood stabilizer within 7 day start ziprasidone . Patients currently receive clozapine . Patients immediate risk commit harm self others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>